Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Ultrasound Molecular Imaging Advances Noninvasive Diagnosis of NASH

By MedImaging International staff writers
Posted on 23 Jan 2024
Print article
Image: Sequential ultrasound molecular imaging is an emerging strategy for the identification of NASH (Photo courtesy of 123RF)
Image: Sequential ultrasound molecular imaging is an emerging strategy for the identification of NASH (Photo courtesy of 123RF)

Non-alcoholic fatty liver disease (NAFLD), recently rebranded as metabolic dysfunction-associated fatty liver disease (MAFLD), encompasses a range of conditions from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH). The most reliable method for diagnosing NASH has been invasive liver biopsy, evaluating histopathological features like liver steatosis, ballooning, and lobular inflammation. Despite its accuracy, liver biopsy has limitations, including sampling bias, low acceptance among patients, and the risk of complications. Existing clinical imaging methods like ultrasound and magnetic resonance imaging (MRI) can detect or quantify liver steatosis but fall short in distinguishing between NASH and NAFLD. This underscores the need for noninvasive markers that can effectively indicate the histologic characteristics of NASH.

Researchers from Sun Yat-sen University (Guangdong, China) have advanced a novel approach known as sequential ultrasound molecular imaging (USMI). for identifying NASH by visualizing hepatic steatosis and inflammation. In this study, they employed specific microbubbles (MBs) targeting CD36 and ICAM-1 separately, rather than using dual-targeted MBs. This strategy enables the differentiation of the sources of the signals, whether stemming from steatosis or inflammation and identifies which pathological change is predominant. CD36 is associated with liver steatosis, while increased ICAM-1 levels are linked to the progression of liver inflammation. Therefore, quantitatively visualizing hepatic CD36 and ICAM-1 could provide critical insights into the severity of hepatic steatosis and inflammation. This research marks a significant stride towards achieving the ultimate goal of developing a reliable, noninvasive method for NASH detection.

“As a noninvasive diagnostic tool, this strategy has the potential to assist in clinical therapeutic decision-making and contribute to drug development for NASH,” said Tinghui Yin, lead author of the study. “Furthermore, among various sequential USMI-based diagnostic models, the serial testing model showed high diagnostic performance in detecting NASH, with 95% sensitivity, 97% specificity, 95% positive predictive values, 97% negative predictive values and 96% accuracy.”

Related Links:
Sun Yat-sen University

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
1.5T MRI System
uMR 670
Computed Tomography (CT) Scanner
Aquilion Serve SP
Color Doppler Ultrasound System
DRE Crystal 4PX

Print article

Channels

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.